《新股消息》匯森家居(02127.HK)發售價定於1.77元 一手中籤率20%
明日掛牌上市的家具產品製造商匯森家居(02127.HK)公布發售價及配發結果,計劃發售7.5億股股份原定其中10%在港公開發售,公開發售部份錄得53.4倍認購,經重新分配後,相關部份股價增至3億股,為整體發行之40%。國際發售初步提呈的發售股份獲踴躍超額認購約2.25倍
每股發售價定於每股1.77元,招股價區間則為每股1.57元至1.86元,一手中籤率20%,抽十五手穩獲一手。集資所得淨額為12.64億元。根據相關定價,基石投資者認購3.52億股,佔公司緊隨全球發售完成後全部已發行股本11.7%。而中信建投國際為獨家保薦人。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.